Testing blood markers linked to how well radiation works
Part of Cancer, Ear, nose & throat, Kidney & urinary, Mouth & dental clinical trials.
This study looks for “biomarkers,” or measurable signs (often from blood or samples), that may show which cancers respond better to radiation therapy. It may help doctors choose radiation treatment more precisely, especially for people who had significant side effects before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had severe (very bad) side effects from radiotherapy (radiation therapy).
- You have a type of cancer that tends to be sensitive to radiotherapy (radiation).
- You are at least 21 years old.
- You are younger than 99 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a blood test can predict severe late side effects from radiation therapy for prostate cancer. The goal is to find out who might be at higher risk, so doctors can better plan treatment and reduce discomfort.
This study collects and measures “biomarkers” (measurable signs in the body) from people with prostate cancer who are about to have surgery or radiation. The goal is to understand how prostate cancer behaves during treatment, which may help improve care in the future.
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
This study looks at tumor tissue and/or blood “biomarkers” to help predict whether a solid tumor will respond well to radiation therapy. It may help doctors choose more effective treatments in the future, and it may guide your care during radiotherapy if you qualify.
This study looks at a simple blood test to help predict how well your tumor will respond to radiation therapy. By measuring a protein called CHI3L1 in your blood before and during treatment, the study aims to help doctors personalize your care.
This trial looks for biomarkers (biological signs) in breast tissue that might predict how well breast cancer responds to radiation therapy. It is for patients with ductal carcinoma in situ (DCIS) who are scheduled to receive radiation after surgery.
Hear when a new Nasopharyngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.